CRIS Current Research Information System

TREVISANI, FRANCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.576
AS - Asia 14.819
EU - Europa 10.953
SA - Sud America 921
AF - Africa 790
Continente sconosciuto - Info sul continente non disponibili 715
OC - Oceania 30
Totale 45.804
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.306
VN - Vietnam 4.617
SG - Singapore 3.678
CN - Cina 3.288
GB - Regno Unito 2.510
IT - Italia 2.227
DE - Germania 1.305
SE - Svezia 1.080
HK - Hong Kong 1.052
FR - Francia 757
IN - India 720
BR - Brasile 653
RU - Federazione Russa 565
UA - Ucraina 551
IE - Irlanda 450
NL - Olanda 357
BD - Bangladesh 283
CH - Svizzera 268
JP - Giappone 255
ZA - Sudafrica 241
KR - Corea 232
TG - Togo 228
FI - Finlandia 223
EE - Estonia 193
CA - Canada 130
CI - Costa d'Avorio 122
AR - Argentina 107
JO - Giordania 100
BG - Bulgaria 93
PH - Filippine 89
SC - Seychelles 81
AT - Austria 77
TH - Thailandia 75
ID - Indonesia 70
ES - Italia 46
TR - Turchia 46
MX - Messico 45
PL - Polonia 44
TW - Taiwan 44
BE - Belgio 43
EC - Ecuador 43
PK - Pakistan 39
IQ - Iraq 37
UZ - Uzbekistan 37
IR - Iran 33
CO - Colombia 32
CL - Cile 29
GR - Grecia 28
AU - Australia 24
SA - Arabia Saudita 24
NG - Nigeria 23
CR - Costa Rica 22
HR - Croazia 20
JM - Giamaica 20
MA - Marocco 20
MY - Malesia 17
VE - Venezuela 17
EG - Egitto 16
LT - Lituania 16
PY - Paraguay 16
RO - Romania 16
CZ - Repubblica Ceca 15
LB - Libano 14
AE - Emirati Arabi Uniti 13
HU - Ungheria 13
ET - Etiopia 12
SV - El Salvador 10
TN - Tunisia 10
DZ - Algeria 9
HN - Honduras 9
PE - Perù 9
DK - Danimarca 8
KZ - Kazakistan 8
LU - Lussemburgo 8
NI - Nicaragua 8
PT - Portogallo 8
BO - Bolivia 7
NP - Nepal 7
OM - Oman 7
AZ - Azerbaigian 6
IL - Israele 6
TT - Trinidad e Tobago 6
UY - Uruguay 6
EU - Europa 5
KE - Kenya 5
MK - Macedonia 5
LV - Lettonia 4
MD - Moldavia 4
RS - Serbia 4
XK - ???statistics.table.value.countryCode.XK??? 4
AL - Albania 3
BY - Bielorussia 3
CM - Camerun 3
CY - Cipro 3
DO - Repubblica Dominicana 3
GE - Georgia 3
GH - Ghana 3
NZ - Nuova Zelanda 3
PR - Porto Rico 3
PS - Palestinian Territory 3
Totale 45.040
Salva come PNG Salva come JPEG
Città #
Singapore 2.434
Southend 2.163
Fairfield 1.734
Ashburn 1.607
Chandler 1.112
Ho Chi Minh City 1.082
San Jose 1.032
Hanoi 977
Hong Kong 970
Woodbridge 756
Santa Clara 723
Houston 671
Seattle 662
Wilmington 649
Princeton 556
Cambridge 546
Dong Ket 540
Bologna 469
Hefei 463
Dublin 446
Council Bluffs 440
Boardman 436
Beijing 376
Ann Arbor 364
Jacksonville 364
Los Angeles 318
Lauterbourg 297
Bern 238
Lomé 227
Westminster 227
Nanjing 226
Tokyo 219
New York 213
Dallas 199
Padova 199
Milan 197
Seoul 180
Da Nang 170
Helsinki 167
Berlin 161
Buffalo 144
Haiphong 139
Abidjan 122
São Paulo 106
Saint Petersburg 105
Shenyang 103
San Diego 100
Amman 99
Jinan 99
Rome 98
Florence 95
Munich 92
Sofia 90
Changsha 86
Frankfurt am Main 82
Medford 81
Turin 80
Redondo Beach 79
Hebei 75
Nanchang 72
Shanghai 69
Guangzhou 68
Mülheim 68
Chicago 67
Redmond 67
Dearborn 64
Tianjin 60
London 59
Phoenix 58
Hải Dương 56
Orem 54
Hangzhou 52
Bengaluru 50
Biên Hòa 49
Des Moines 47
Redwood City 47
Zhengzhou 46
Amsterdam 45
The Dalles 44
Bremen 43
Can Tho 42
Nuremberg 41
Vienna 41
Brooklyn 39
Falls Church 38
Mahé 38
Norwalk 38
Olalla 38
Brussels 36
Denver 35
Johannesburg 35
Ninh Bình 35
Falkenstein 34
San Francisco 34
Jiaxing 33
Mountain View 32
Atlanta 30
Bến Tre 30
Montreal 30
Quận Bình Thạnh 30
Totale 28.579
Salva come PNG Salva come JPEG
Nome #
The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. 362
TACE treatment in hepatocellular carcinoma: what should we do now? 359
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 330
Efficacy of radioembolization according to tumor morphology and portal vein thrombosis inintermediate-advanced hepatocellular carcinoma 315
Monofocal hepatocellular carcinoma: How much does size matter? 302
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 294
g-hydroxybutyrate as a treatment for alcoholism. 275
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 271
Alcol, sindrome feto-alcolica, apparato ematopoietico, muscolo-scheletrico, respiratorio, cute e reni. 262
Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: A tale of multiple confounders 262
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 256
Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study 251
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 249
Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications 248
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 246
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 246
Pattern of macrovascular invasion in hepatocellular carcinoma 246
A novel sodium overload test predicting ascites decompensation in rats with CCl4-induced cirrhosis. 244
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study 243
Hyperkeratosis of nipple skin during sorafenib treatment 240
Oxidative injury in rat fatty liver exposed to ischemia-reperfusion is modulated by nutritional status. 230
C-11 Acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma. 230
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma 229
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study 228
The changing scenario of hepatocellular carcinoma in Italy: an update 227
The nutritional status modulates preservation-reperfusion injury in rat fatty liver. 226
Art in hospital: its impact on the feelings and emotional state of patients admitted to an Internal Medicine Unit. 226
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 226
BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. 225
A novel sodium overload test predicting ascites decompensation in rats with CCL4-induced cirrhosis. 224
Prognostication of the outcome of hepatocellular carcinoma: how to rely on science instead of the art of Nostradamus 223
Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group 222
Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma 220
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 219
Combined mechanical and pharmacologic thrombolysis for portal vein thrombosis in liver-graft recipients and in candidates for liver transplantation. 217
Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib 214
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 214
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome. 213
Differential diagnosis between focal nodular hyperplasia and hepatocellular adenoma: Potential role of double tracer PET with 11C-Acetate and 18F-FDG 213
The reduced tolerance of rat fatty liver to ischemia-reperfusion is associated to mitochondrial oxidative injury. 212
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 211
Long-term beta-blockade shortens Qt interval prolongation in patients with liver cirrhosis 210
Muscle circulation contributes to hyperdynamic circulatory syndrome in advanced cirrhosis. 210
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 210
Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20 year multicentre experience. 209
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 209
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA. database 209
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 207
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients 203
Cardiac electrophysiological abnormalities in patients with cirrhosis. 201
Metabolic disorders across hepatocellular carcinoma in Italy 201
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 199
Basi scientifiche per la definizione delle linee guida in ambito clinico per l’epatocarcinoma. 199
C-type natriuretic peptide (CNP) favours natriuresis in pre-ascitic cirrhotic patients. 196
Daily profile of circulating c-type natriuretic peptide in pre-ascitic cirrhosis and in normal subjects. Relationship with renal function. 194
Recent advances in the natural history of hepatocellular carcinoma. 194
Retrospective analysis of dose–response for HCC lesions treated with 90Y resin microspheres. 194
Transthoracic electrical bioimpedance: a non-invasive technique for the evaluation of the hemodynamic alterations in patients with liver cirrhosis. 194
Trattamento farmacologico della intossicazione acuta, sindrome post-sbornia e sindrome d’astinenza da alcol. 193
Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis. 192
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice 192
Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis. Effects on cancer staging and patients survival. 192
Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis 191
Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. 190
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. 190
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. 190
Insufficienza epatica acuta ed epatite subacuta. 189
Gamma-hydroxybutyric acid plus naltrexone in the treatment of alcoholics resistant to monotherapy. 188
Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma 188
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. 188
Alfa-fetoprotein in hepatocellular carcinoma (HCC): diagnostic and prognostic role, clinical and biological predictors. Analysis of 1099 patients. 187
Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischemia-reperfusion injury complicated by endotoxemia. 185
Immunotherapy with checkpoint inhibitors for hepatocellular carcinoma: Where are we now? 185
QT Interval Correction in Patients with Cirrhosis 184
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 184
Alcohol misuse and traffic accidents 183
Ablation and resection for hepatocellular carcinoma within Milan criteria and high alpha-foetoprotein levels 183
Terlipressin infusion induces ischemia of breast skin in a cirrothic patient with hepatorenal syndrome 182
Development and validation of a scoring system that includes corrected QT interval for risk analysis of patients with cirrhosis and gastrointestinal bleeding 181
Telangiectasia as a presenting sign of Graves’ disease. 180
Small (≤3cm) Hepatocellular Carcinoma in Cirrhosis: the Role of Double Contrast Agents MR Imaging vs. Multi-Detector Row CT 179
Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma 178
Suppression of craving for gamma-hydroxybutyric acid by naltrexone administration: three case reports. 177
Alcolismo 177
QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. 177
Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma 177
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 177
Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma 176
How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. 175
Torsade de pointes” during amiodarone infusion in cirrhotic woman with the prolonged QT interval. 174
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 173
Portal vein arterialization increases liver regeneration in acute liver failure induced by extended hepatectomy or toxin administration in the rat 172
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study 172
Hepatic decompensation is the major driver of death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. 172
High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing Lamivudine resistance. 171
Storia naturale dell’epatocarcinoma. 171
Retrospective analysis of dose-response for HCC lesions treated with 90Y resin microspheres. 171
Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. 170
Is it time to extend criteria for hepatic resection in the treatment of hepatocellular carcinoma? 170
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment 169
Totale 21.184
Salva come PNG Salva come JPEG
Categoria #
all - tutte 128.998
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 128.998
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.327 0 167 267 343 429 244 104 323 196 251 1.272 731
2022/20235.084 510 757 265 596 330 363 178 259 902 125 415 384
2023/20241.568 104 239 112 133 147 283 114 102 111 102 60 61
2024/20255.807 183 896 517 395 1.008 300 385 151 80 428 231 1.233
2025/202615.934 1.425 1.071 1.236 1.034 1.473 839 2.128 686 3.082 1.233 946 781
2026/2027985 434 551 0 0 0 0 0 0 0 0 0 0
Totale 45.804